Release time：Aug 08, 2021
On the afternoon of August 5, 2021, Zhang Quan, director of Science and Technology Commission of Shanghai Municipality, and his team made an inspection to Mabwell. Accompanied by Dr. Liu Datao, founder and CEO of the company, Zhang Quan and his team visited Mabwell's R&D Center for biological antibody drugs and learned about the company's continuous innovative strength in developing efficient biological antibody products.
During the inspection, Dr. Liu Datao reported the development history and work progress of Mabwell to Director Zhang Quan and other leaders of the Science and Technology Commission. In his report, Dr. Liu focused on the company's strategy of building the capability of sustained innovation strength as the core, creating an innovative system which is underpinned by the discovery of antibody drug molecules and covers every aspects in the entire cycle of drug R&D including druggability study, preclinical study, clinical study and production transformation and ultimately completing the layout of the entire industrial chain and achieving the global commercialization goals. With the continuous development, Mabwell has formed innovation-oriented and comprehensive product pipelines. The company has undertaken one national major science and technology project, one key science and technology project, two national major R&D projects and several provincial and municipal science and technology innovation projects. Currently, Mabwell has 9 products in different clinical phases. In particular, during the development of antibody drugs for the prevention and control of COVID-19 epidemic, Mabwell was the first pharmaceutical company to advance the antibody drugs intended for the treatment of COVID-19 to phase II clinical studies in China and has also conducted multi-center clinical trials for these drugs internationally. So Mabwell has made certain achievements in this field.
After listening to Dr. Liu Datao's report, Director Zhang Quan fully acknowledged Mabwell's strength of making continuous innovations as well as the achievements made by actively participating in science and technology researches. Director Zhang pointed out that in face of the outbreak of COVID-19 epidemic, Shanghai municipal government actively organized all forces from various sectors to tackle the problem with collaborative efforts, and achieved a number of innovative scientific and technological achievements, which well reflected the scientific and technological accumulation over the years by various excellent enterprises such as Mabwell. Mabwell and other pharmaceutical companies have contributed "Shanghai Power" to the fight against the epidemic. Director Zhang further stated that due to the continuous mutation of coronavirus, the domestic epidemic prevention and control situation is still grim and complex, and he hoped that Mabwell would further exert its hardcore strength of combating COVID-19 epidemic with science and technology, continue to carry out front-end research and make continuous breakthroughs in the innovation and development of antibody drugs, so as to provide more powerful and cutting-edge scientific and technological support for epidemic prevention and control. Moreover, he hoped that Mabwell would continue to promote more independent R&D innovative projects, give a full play to its hardcore strengths of harnessing science and technology to contribute to the innovative development of the Chinese biopharmaceutical industry and benefit more patients.
The main leaders of the Science and Technology Commission Office of Shanghai Municipality, the Biomedicine Department and related responsible persons in Mabwell participated in the meeting.
